Heaptalk, Jakarta — Singapore’s health deep tech startup, Mesh Bio, announced its new funding milestone in a Series A round at US$3.5 million led by East Ventures. Elev8, Seed Capitals, and other existing shareholders also back this investment. Prior to seizing this new injection, the startup also landed a Seed funding round at US$1.8 million in October 2021.
The funding will allow Mesh Bio to offer its digital twin technologies to healthcare providers and scale the deployment of these solutions across Hong Kong and Southeast Asia, primarily Indonesia and the Philippines.
“We are excited to announce the closure of our Series A funding. This pivotal step empowers us to broaden our digital health solutions for chronic disease management in Southeast Asia,” said Co-Founder and Chief Executive Officer of Mesh Bio, Andrew Wu.
Southeast Asia presents myriad unmet healthcare needs. Moreover, the high prevalence of chronic diseases, such as diabetes and heart disease, in the region, has pushed more general practitioners who lack specialist training in endocrinology to manage patients with chronic diseases. For this reason, Mesh Bio focuses on addressing these gaps effectively by delivering digital solutions and offering patient data and predictive analytics that equip doctors with information and intelligence about their patients and the diseases they live with.
Its digital platform, DARA Health Intelligence, enables data-driven care delivery, which improves patient engagement and health outcomes. The platform has been operated by over 120 medical centers across Singapore, Malaysia, and Indonesia for preventive health screening. This platform has also been expanded to chronic disease management with HealthVector Diabetes.
Leading Mesh Bio’s investment, Co-Founder and Managing Partner of East Ventures, Willson Cuaca realized the startup stands out with its leading-edge technology that is set to revolutionize patient care delivery, particularly in today’s rapidly evolving healthcare landscape. Based on his observation, Mesh Bio’s innovative approach to harnessing predictive analytics would be a game changer in enabling more personalized and preventive healthcare services.
“We look forward to further cooperation in transforming the healthcare system in Southeast Asia and beyond,” Willson affirmed.
The new investment comes three months after the startup secured historic regulatory approval and an implementation pilot with public health systems for one of the digital twin technologies in Singapore. This represents a significant opportunity to improve patient outcomes from diseases.
In October 2023, Mesh Bio obtained Singapore’s Health Sciences Authority (HSA) approval to market its HealthVector Diabetes as a Software Medical Device (SaMD). HealthVector Diabetes is currently used in an implementation pilot at Singapore General Hospital (SGH), Tan Tock Seng Hospital (TTSH), and selected polyclinics for potential clinical adoption.
